黃連及小檗鹼奈米微脂體的抗人類肝癌細胞作用之分析與細胞凋亡機制之探討

溫曉薇
國立中興大學
中草藥是中國五千年來的傳統資產，並已發展出許多治療疾病的方法，且目前中草藥對某些疾病的療效已受到西方醫學的證實。肝癌為國人癌症死因第一或第二位，當前急需研發出有效的抗癌物質以對抗肝癌。而黃連具有抗菌、抗病毒、抗發炎等作用，近來許多研究指出黃連或小檗鹼具有抗肝癌、乳癌及鼻咽癌的功效。另外，微脂體可包裹疏水性與親水性的藥物，為良好的藥物傳輸載體，且已有上市產品運用於乳癌的治療。故本實驗目的是將黃連萃液或小檗鹼水溶液以微脂體包裹後作用在肝癌細胞，期望經由微脂體包裹並經奈米化之後可提高對黃連萃液或小檗鹼水溶液對肝癌細胞的殺害能力，並降低對正常細胞的副作用，繼之以動物模式進行最適劑型及最適量的體內評估。另外，將探討黃連或小檗鹼奈米微脂體對肝癌細胞凋亡的機制，以確實了解此藥物對抗肝癌的細胞作用機制。
關鍵字：黃連；小檗鹼；奈米微脂體

Analysis of anticancer effects of huang-lian and berberine liposomal nanovesicles on human hepatocellular carcinoma and investigation of their apoptotic pathways

Hsiao-Wei Wen
National Chung Hsing University
Traditional Chinese medicine has five thousand year history and has developed many treatments for various diseases. Moreover, some therapeutic effects of traditional Chinese medicine have been proved by Western medicine. Liver cancer ranks as the first or second in the cancer death rates in Taiwan. Huang-lian possesses antibacterial, antiviral and anti-inflammation effects, and recently huang-lian and berberine have been proved to have anticancer effects against liver, breast and nasopharyngeal cancers. In addition, liposome is a good drug carrier for both hydrophilic and hydrophobic drugs and there already have liposomal drugs in the market for treating breast cancer. Therefore, the objective of this study is to use liposomal nanovesicles as the drug carrier to encapsulate samples of huang-lian or berberine, in order to enhance their anticancer effects on hepatocellular carcinoma cells (HCC) and simultaneously to reduce their side effects on normal cells. Moreover, the in vivo nude mouse model will be applied to evaluate the optimal formuation and dose. Finally, their apoptotic pathways will be studied for understand their anticancer mechanisms in HCC.
關鍵字：huang-lian；berberine；liposomal nanovesciles